Spots Global Cancer Trial Database for Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
Official Title: A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia
Study ID: NCT03516760
Interventions
Study Description
Brief Summary: This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Universitätsmedizin Mannheim, Mannheim, Baden-Württemberg, Germany
Klinikum rechts der Isar, München, Bayern, Germany
Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
Universitätsklinikum Marburg, Marburg, Hessen, Germany
Universitätsklinikum Dresden, Dresden, Sachsen, Germany
Charité Universitätsmedizin, Berlin, , Germany
Contact Details
Name: Martin Wermke, MD
Affiliation: Universitätsklinikum Carl Gustav Carus Dresden
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
